ConferenceCancer Research · April 3, 2026
AbstractThe World Health Organization provides clear criteria for diagnosing IDH1-wildtype glioblastoma (GBM), relying on traditional approaches to define pathoetiological features, genomic mutations, cop ...
Full textCite
ConferenceNeuro-Oncology · November 11, 2025
AbstractThe World Health Organization provides clear criteria for diagnosing IDH1-wildtype glioblastoma (GBM), relying on traditional approaches to define pathoetiological features, genomic mutations, cop ...
Full textCite
ConferenceNeuro-Oncology · November 11, 2025
AbstractBACKGROUNDIdentification of biomarkers for overall survival (OS) in oligodendroglioma has proven challenging due to 1) ...
Full textCite
ConferenceNeuro-Oncology · November 11, 2024
AbstractBrain metastases are the most common form of intracranial tumor in adults, however the prognosis remains dismal due to lack of effective treatments and limited understanding of the underlying physiol ...
Full textCite
ConferenceNeuro-Oncology · November 11, 2024
AbstractOligodendrogliomas are progressive, infiltrative gliomas. While new molecular criteria were introduced in 2016 for diagnosing oligodendroglioma, the grading criteria remains largely unchanged. We eva ...
Full textCite
ConferenceCancer Research · March 22, 2024
AbstractIntroduction: The diverse tumor environment of high-grade glioma, which remains refractory to treatment, demands new innovative, multi-omic approaches to characterize tumor heterogeneity and expressi ...
Full textCite
ConferenceNeuro-Oncology · June 12, 2023
AbstractGangliogliomas are glioneuronal brain tumors that typically present in childhood or early adulthood. Though most often low-grade, new insights are needed to refine glioneuronal tumor classification a ...
Full textCite
ConferenceCell Mol Gastroenterol Hepatol · 2023
BACKGROUND & AIMS: Nonalcoholic steatohepatitis (NASH), a leading cause of cirrhosis, strongly associates with the metabolic syndrome, an insulin-resistant proinflammatory state that disrupts energy balance and promotes progressive liver degeneration. We a ...
Full textLink to itemCite
ConferenceProstate Cancer Prostatic Dis · September 2022
BACKGROUND: Prostate cancer is a clinically and molecularly heterogeneous disease, with highest incidence and mortality among men of African ancestry. To date, prostate cancer patient-derived xenograft (PCPDX) models to study this disease have been difficu ...
Full textOpen AccessLink to itemCite
ConferenceJournal of Clinical Oncology · February 20, 2022
139 Background: Androgen receptor signaling inhibitors (ARSi) are a mainstay for patients with metastatic castration-resistant prostate cancer (mCRPC). However, patient response is heterogeneous and the molecular underpinnings of ...
Full textCite
ConferenceJOURNAL OF CLINICAL ONCOLOGY · 2022
Background: High-grade gliomas (HGGs) are immunologically ‘cold’ tumors. This phenomenon is partly due to reduced expression of major histocompatibility class (MHC) I on the surface of tumor cells, which prevents CD8+ cytotoxic T lymphocyte activity (CTLs) ...
Full textLink to itemCite
ConferenceMol Cancer Res · June 2021
Men with circulating tumor cell (CTC) AR-V7-positive metastatic castration-resistant prostate cancer (mCRPC) have worse outcomes when treated with enzalutamide/abiraterone. However, most men lack CTC AR-V7 detection, and additional predictive biomarkers ar ...
Full textLink to itemCite
ConferenceJournal of Clinical Oncology · February 20, 2018
160 Background: Radium-223 is a targeted alpha therapy that improves survival in men with mCRPC. The biologic basis for radium-223 efficacy is not completely understood. We hypothesized that PC osteomimicry, a form of epithelial ...
Full textCite
ConferenceJournal of Clinical Oncology · February 1, 2014
65 Background: Given the evolving treatments available in metastatic castration resistant prostate cancer (mCRPC), predictive biomarkers are desirable that maximize benefit and minimize harms and costs.The goal of this study was ...
Full textCite
ConferenceMed Pediatr Oncol · January 2001
BACKGROUND: Chromosome 1p deletions are common in advanced neuroblastomas, but the biological and clinical implications of this clonal rearrangement remain controversial. Previous studies of chromosome 1p loss of heterozygosity (LOH) have been limited by a ...
Full textLink to itemCite